Week In Review: Innovent Biologics And Eli Lilly Sign $1 Billion Cancer Deal

Innovent Biologics of Suzhou and Eli Lilly (NYSE: LLY) expanded their 10-year collaboration formed in March this year, granting Lilly ex-China rights to three new anti-PD-1 cancer drugs developed by Innovent (see story). Innovent will receive more than $1 billion in milestones in total from Lilly, plus potential royalties. Innovent will develop, manufacture and commercialize the drugs inside China, while Lilly will do the same outside of China.

Help employers find you! Check out all the jobs and post your resume.